Motus GI Holdings, Inc. (MOTS): Price and Financial Metrics


Motus GI Holdings, Inc. (MOTS): $0.28

-0.02 (-6.13%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

MOTS Stock Summary

  • MOTS has a higher market value than only 2.76% of US stocks; more precisely, its current market capitalization is $18,876,478.
  • MOTS's price/sales ratio is 57.55; that's higher than the P/S ratio of 96.5% of US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for MOTS comes in at -70.87% -- higher than that of only 5.91% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Motus GI Holdings Inc are DMRC, DOMO, PD, NTNX, and RPD.
  • Visit MOTS's SEC page to see the company's official filings. To visit the company's web site, go to www.motusgi.com.

MOTS Valuation Summary

  • In comparison to the median Healthcare stock, MOTS's EV/EBIT ratio is 103.75% lower, now standing at -1.1.
  • MOTS's price/sales ratio has moved NA NA over the prior 43 months.
  • MOTS's price/earnings ratio has moved up 3.6 over the prior 43 months.

Below are key valuation metrics over time for MOTS.

Stock Date P/S P/B P/E EV/EBIT
MOTS 2021-08-31 170.5 2.1 -1.6 -1.1
MOTS 2021-08-30 170.5 2.1 -1.6 -1.1
MOTS 2021-08-27 170.0 2.1 -1.6 -1.1
MOTS 2021-08-26 171.8 2.1 -1.6 -1.1
MOTS 2021-08-25 172.3 2.2 -1.6 -1.2
MOTS 2021-08-24 169.5 2.1 -1.6 -1.1

MOTS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MOTS has a Quality Grade of F, ranking ahead of 2.21% of graded US stocks.
  • MOTS's asset turnover comes in at 0.008 -- ranking 170th of 186 Medical Equipment stocks.
  • 500 - Internal server error

The table below shows MOTS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.008 -1.391 -8.260
2021-03-31 0.005 -3.083 -7.460
2020-12-31 0.004 -4.061 -8.708
2020-09-30 0.006 0.112 -5.005
2020-06-30 0.005 -0.321 -3.413
2020-03-31 0.005 -0.231 -3.489

MOTS Price Target

For more insight on analysts targets of MOTS, see our MOTS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $2.03 Average Broker Recommendation 1.25 (Strong Buy)

MOTS Stock Price Chart Interactive Chart >

Price chart for MOTS

MOTS Price/Volume Stats

Current price $0.28 52-week high $1.06
Prev. close $0.30 52-week low $0.23
Day low $0.27 Volume 598,391
Day high $0.30 Avg. volume 1,121,763
50-day MA $0.27 Dividend yield N/A
200-day MA $0.43 Market Cap 15.50M

Motus GI Holdings, Inc. (MOTS) Company Bio


Motus GI Holdings, Inc., a development stage company, engages in developing single-use medical device systems in the United States. It is developing Pure-Vu system that integrates with existing colonoscopes to cleanse poorly prepped colons during the colonoscopy procedure. The company is based in Tirat Carmel, Israel.


MOTS Latest News Stream


Event/Time News Detail
Loading, please wait...

MOTS Latest Social Stream


Loading social stream, please wait...

View Full MOTS Social Stream

Latest MOTS News From Around the Web

Below are the latest news stories about Motus GI Holdings Inc that investors may wish to consider to help them evaluate MOTS as an investment opportunity.

Motus GI Granted 180-Day Extension to Meet NASDAQ Minimum Bid Price Requirement

FORT LAUDERDALE, Fla., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today announced that the Company received written notification from the Listing Qualification Department of The NASDAQ Capital Market ("Nasdaq") granting the Company's reque

Yahoo | February 24, 2022

Motus GI Holdings Inc. Is A Buy Small Cap Stock: Analysts

Motus GI Holdings Inc. (NASDAQ:MOTS) has a beta value of 2.41 and has seen 2.49 million shares traded in the last trading session. The company, currently valued at $16.71M, closed the last trade at $0.35 per share which meant it lost $0.0 on the day or 2.08% during that session. The MOTS stock price is Motus GI Holdings Inc. Is A Buy Small Cap Stock: Analysts Read More »

Marketing Sentinel | February 22, 2022

H.C. Wainwright Thinks Motus Gi Holdings’ Stock is Going to Recover

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Motus Gi Holdings (MOTS – Research Report) today and set a price target of $2.00. The company's shares closed last Monday at $0.44, close to its 52-week low of $0.32. According to TipRanks.com, Chen is a 5-star analyst with an average return of 15.8% and a 36.3% success rate. Chen covers the Healthcare sector, focusing on stocks such as Ortho Clinical Diagnostics Holdings, Interpace Diagnostics Group, and HTG Molecular Diagnostics. Motus Gi Holdings has an analyst consensus of Strong Buy, with a price target consensus of $2.25, a 280.1% upside from current levels.

Brian Anderson on TipRanks | February 15, 2022

Motus GI Stock Surges On FDA Approval For Next-Gen Pure-Vu EVS System

The FDA has granted 510(k) clearance to Motus GI Holdings Inc's (NASDAQ: MOTS) upgraded Pure-Vu EVS System. The new Pure-Vu EVS System is intended to improve the speed of set-up, enhance navigation capabilities in tortuous anatomy, build upon the Pure-Vu system's cleansing capabilities, and enable physicians to rapidly overcome the challenges of poorly prepared colons during a colonoscopy. The Pure-Vu platform facilitates the cleaning of a poorly prepared colon to improve visualization during th

Yahoo | February 14, 2022

Motus GI Receives FDA Clearance to Market the Pure-Vu® EVS System

-All New Pure-Vu EVS offers rapid set-up, improved navigation and enhanced cleansing capabilities to support expanded clinical utilization -Scientific literature shows ~51% of hospitalized inpatient colonoscopies are delayed due to insufficient bowel prep leading to unnecessary extended hospitalizations -Pure-Vu EVS commercialization in US market expected to commence immediately FORT LAUDERDALE, Fla., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "C

Yahoo | February 14, 2022

Read More 'MOTS' Stories Here

MOTS Price Returns

1-mo 0.21%
3-mo -22.24%
6-mo -40.04%
1-year -73.08%
3-year -90.64%
5-year N/A
YTD -40.04%
2021 -50.74%
2020 -58.60%
2019 -26.37%
2018 N/A
2017 N/A

Continue Researching MOTS

Want to see what other sources are saying about Motus GI Holdings Inc's financials and stock price? Try the links below:

Motus GI Holdings Inc (MOTS) Stock Price | Nasdaq
Motus GI Holdings Inc (MOTS) Stock Quote, History and News - Yahoo Finance
Motus GI Holdings Inc (MOTS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6289 seconds.